Navigation Links
New gene variant may explain psychotic features in bipolar disorder
Date:3/5/2013

Researchers at Karolinska Institutet in Sweden have found an explanation for why the level of kynurenic acid (KYNA) is higher in the brains of people with schizophrenia or bipolar disease with psychosis. The study, which is published in the scientific periodical Molecular Psychiatry, identifies a gene variant associated with an increased production of KYNA. The discovery contributes to the further understanding of the link between inflammation and psychosis and might pave the way for improved therapies.

Kynurenic acid (KYNA) is a substance that affects several signalling pathways in the brain and that is integral to cognitive function. Earlier studies of cerebrospinal fluid have shown that levels of KYNA are elevated in the brains of patients with schizophrenia or bipolar diseases with psychotic features. The reason for this has, however, not been fully understood.

KMO is an enzyme involved in the production of KYNA, and the Karolinska Institutet team has now shown that some individuals have a particular genetic variant of KMO that affects its quantity, resulting in higher levels of KYNA. The study also shows that patients with bipolar disease who carry this gene variant had almost twice the chance of developing psychotic episodes.

KYNA is produced in inflammation, such as when the body is exposed to stress and infection. It is also known that stress and infection may trigger psychotic episodes. The present study provides a likely description of this process, which is more likely to occur in those individuals with the gene variant related to higher production of KYNA. The researchers also believe that the discovery can help explain certain features of schizophrenia or development of other psychotic conditions.

"Psychosis related to bipolar disease has a very high degree of heredity, up to 80 per cent, but we don't know which genes and which mechanisms are involved," says Martin Schalling, Professor of medical genetics at Karolinska Institutet's Department of Molecular Medicine and Surgery, also affiliated to the Center for Molecular Medicine (CMM). "This is where our study comes in, with a new explanation that can be linked to signal systems activated by inflammation. This has consequences for diagnostics, and paves the way for new therapies, since there is a large arsenal of already approved drugs that modulate inflammation."


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert

Related biology news :

1. Common genetic variants identify autism risk in high risk siblings of children with ASD
2. Ingenuity Variant Analysis Sees Exponential Customer Adoption
3. Dopamine-receptor gene variant linked to human longevity
4. Surprising pine beetle breeding habits help explain increasing tree damage, says CU study
5. Computer simulations help explain why HIV cure remains elusive
6. Genetic variation in East Asians found to explain resistance to cancer drugs
7. Growing nitrous oxide levels explained
8. Overweight? New research explains how proper sleep is important for healthy weight
9. A cells first steps: Building a model to explain how cells grow
10. Scientists start explaining Fat Bastards vicious cycle
11. The appetite-suppressing effect of proteins explained
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Savannah River ... technologies and selected NewTechBio,s NT-MAX Lake & ... based beneficial bacteria, in conjunction with Hexa Armor/ ... deficiencies with National Pollutant Discharge Elimination System requirements. ... experienced a steady history of elevated pH levels, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
(Date:12/7/2016)... EDMONTON , Dec. 7, 2016 /PRNewswire/ - ... the development and commercialization of immunotherapeutic products for ... has entered into an Antibody Manufacturing Development Program ... , USA) for its oregovomab antibody product. ... its Phase IIb clinical study in ovarian cancer ...
(Date:12/7/2016)... -- The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication Process ... Global Forecast to 2026", published by MarketsandMarkets, the global market size was USD ... 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo , ...
Breaking Biology Technology: